# Domenico Bilancia

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/domenico-bilancia/

## Facts

| Field | Value |
| --- | --- |
| Citations | 2,140 |
| Field | Colorectal Cancer Treatments and Studies |
| h-index | 22 |
| i10-index | 37 |
| Last Known Institution | Azienda Ospedaliera Ospedale San Carlo Borromeo |
| OpenAlex ID | https://openalex.org/A5089737234 |
| Works | 125 |

## Researcher papers

- [Gemcitabine Plus Vinorelbine Versus Vinorelbine Alone in Elderly Patients With Advanced Non–Small-Cell Lung Cancer](https://scholariq.org/papers/gemcitabine-plus-vinorelbine-versus-vinorelbine-alone-in-elderly-patients-with/)
- [The tale of TILs in breast cancer: A report from The International Immuno-Oncology Biomarker Working Group](https://scholariq.org/papers/the-tale-of-tils-in-breast-cancer-a-report-from-the-international-immuno/)
- [Randomized Trial Comparing Cisplatin, Gemcitabine, and Vinorelbine With Either Cisplatin and Gemcitabine or Cisplatin and Vinorelbine in Advanced Non–Small-Cell Lung Cancer: Interim Analysis of a Phase III Trial of the Southern Italy Cooperative Oncology Group](https://scholariq.org/papers/randomized-trial-comparing-cisplatin-gemcitabine-and-vinorelbine-with-either/)
- [Lapatinib in breast cancer](https://scholariq.org/papers/lapatinib-in-breast-cancer/)
- [Cisplatin, Gemcitabine, and Vinorelbine Combination Therapy in Advanced Non–Small-Cell Lung Cancer: A Phase II Randomized Study of the Southern Italy Cooperative Oncology Group](https://scholariq.org/papers/cisplatin-gemcitabine-and-vinorelbine-combination-therapy-in-advanced-non-small/)
- [Cisplatin-Based First-Line Treatment of Elderly Patients With Advanced Non–Small-Cell Lung Cancer: Joint Analysis of MILES-3 and MILES-4 Phase III Trials](https://scholariq.org/papers/cisplatin-based-first-line-treatment-of-elderly-patients-with-advanced-non-small/)
- [Exploring the associations between spiritual well-being, burden, and quality of life in family caregivers of cancer patients](https://scholariq.org/papers/exploring-the-associations-between-spiritual-well-being-burden-and-quality-of/)
- [Phase III trial comparing 3–6 months of adjuvant FOLFOX4/XELOX in stage II–III colon cancer: safety and compliance in the TOSCA trial](https://scholariq.org/papers/phase-iii-trial-comparing-3-6-months-of-adjuvant-folfox4-xelox-in-stage-ii-iii/)
- [Cisplatin, Gemcitabine, and Paclitaxel in Locally Advanced or Metastatic Non–Small-Cell Lung Cancer: A Phase I-II Study](https://scholariq.org/papers/cisplatin-gemcitabine-and-paclitaxel-in-locally-advanced-or-metastatic-non-small/)
- [HER2-Low Status Does Not Affect Survival Outcomes of Patients with Metastatic Breast Cancer (MBC) Undergoing First-Line Treatment with Endocrine Therapy plus Palbociclib: Results of a Multicenter, Retrospective Cohort Study](https://scholariq.org/papers/her2-low-status-does-not-affect-survival-outcomes-of-patients-with-metastatic/)
- [Does Family Caregiver Burden Differ Between Elderly and Younger Caregivers in Supporting Dying Patients With Cancer? An Italian Study](https://scholariq.org/papers/does-family-caregiver-burden-differ-between-elderly-and-younger-caregivers-in/)

## Researcher topics

- [Colorectal Cancer Treatments and Studies](https://scholariq.org/topics/colorectal-cancer-treatments-and-studies/)
- [Cancer Treatment and Pharmacology](https://scholariq.org/topics/cancer-treatment-and-pharmacology/)
- [Lung Cancer Treatments and Mutations](https://scholariq.org/topics/lung-cancer-treatments-and-mutations/)
- [Breast Cancer Treatment Studies](https://scholariq.org/topics/breast-cancer-treatment-studies/)
- [Gastric Cancer Management and Outcomes](https://scholariq.org/topics/gastric-cancer-management-and-outcomes/)

## Researcher university

- [Azienda Ospedaliera Ospedale San Carlo Borromeo](https://scholariq.org/institutions/azienda-ospedaliera-ospedale-san-carlo-borromeo/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.